Danish cancer vaccine patented in the US
Adaptvac, a joint venture between a Copenhagen University spinout and Danish Expres2ion, has taken out a patent in the US on a new breast cancer vaccine. "An important milestone," says the chairman.
A new, effective and cheap breast cancer vaccine might be under way for patients with HER2-positive breast cancer, which constitutes 20-30 percent of all breast cancer cases.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
